HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Historical Holders from Q1 2014 to Q3 2025

Symbol
HALO on Nasdaq
CUSIP
40637H109
Type / Class
Equity / Common Stock
Shares outstanding
124M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
119M
Holdings value
$8.73B
% of all portfolios
0.009%
Grand Portfolio weight change
+0%
Number of holders
586
Number of buys
287
Number of sells
-283
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 10.2% -22.3% $634M -$177M 12.6M -21.9% BlackRock, Inc. Jun 30, 2025
STATE STREET CORP 4.9% $365M 6.05M STATE STREET CORPORATION Mar 31, 2025

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 119M $8.73B +$218M $73.34 586
2025 Q2 116M $6.05B -$203M $52.02 541
2025 Q1 120M $7.68B -$91.6M $63.81 541
2024 Q4 122M $5.85B -$142M $47.81 497
2024 Q3 124M $7.1B +$131M $57.24 501
2024 Q2 122M $6.4B +$5.32M $52.36 451
2024 Q1 122M $4.97B -$73.7M $40.68 411
2023 Q4 909K $33.6M +$973K $36.96 4
2023 Q3 121M $4.64B +$384K $38.20 384
2023 Q2 121M $4.37B -$98.1M $36.07 364
2023 Q1 123M $4.7B -$296M $38.19 377
2022 Q4 128M $7.31B -$109M $56.90 410
2022 Q3 122M $4.83B +$122M $39.54 337
2022 Q2 125M $5.51B +$52.9M $44.00 353
2022 Q1 126M $5.03B -$48.4M $39.88 292
2021 Q4 127M $5.09B -$91.5M $40.21 309
2021 Q3 127M $5.17B +$15.5M $40.68 312
2021 Q2 127M $5.78B -$73.4M $45.41 304
2021 Q1 131M $5.44B -$157M $41.69 329
2020 Q4 135M $5.77B +$136M $42.71 331
2020 Q3 132M $3.48B -$48.4M $26.28 256
2020 Q2 133M $3.57B +$197M $26.81 249
2020 Q1 130M $2.34B +$49.4M $17.99 200
2019 Q4 127M $2.26B +$8.21M $17.73 215
2019 Q3 124M $1.92B +$57.7M $15.51 200
2019 Q2 122M $2.1B +$235M $17.18 196
2019 Q1 118M $1.91B -$285K $16.10 193
2018 Q4 118M $1.72B -$44.2M $14.63 182
2018 Q3 123M $2.23B +$6.55M $18.17 188
2018 Q2 123M $2.07B -$3.33M $16.87 192
2018 Q1 124M $2.42B +$15.5M $19.59 206
2017 Q4 122M $2.48B +$23.9M $20.26 195
2017 Q3 121M $2.11B -$3.48M $17.37 164
2017 Q2 121M $1.56B +$86.2M $12.82 161
2017 Q1 115M $1.49B +$199M $12.96 154
2016 Q4 111M $1.09B +$44.5M $9.88 164
2016 Q3 106M $1.28B +$17.3M $12.08 161
2016 Q2 105M $907M +$19.5M $8.63 159
2016 Q1 100M $949M +$16.5M $9.47 156
2015 Q4 98.8M $1.71B +$8.21M $17.33 164
2015 Q3 98.1M $1.32B +$3.59M $13.43 172
2015 Q2 94.7M $2.14B +$79.2M $22.58 157
2015 Q1 92.1M $1.32B +$56.8M $14.28 136
2014 Q4 91.2M $880M +$20.2M $9.65 130
2014 Q3 89M $810M +$28.6M $9.10 117
2014 Q2 85.7M $846M -$18.7M $9.88 127
2014 Q1 85.9M $1.09B +$76.3M $12.70 129